Abstract
The term “anticancer drugs” evokes memories of a time when the development of medications in that category was still necessary. Capmatinib, for example, is a kinase inhibitor that targets the C-Met receptor tyrosine kinase in the treatment of non-small cell lung cancer, which involves tissue repair and organ regeneration.1 Thus, utilizing liquid chromatography-tandem mass spectroscopy (LC-MS/MS) in human plasma in accordance with United States Food and Drug Administration (USFDA) bioanalytical technique validation criteria, a quick, simple, specific, dependable, and sensitive approach was created using deucravacitinib as an internal standard. Capmatinib and the internal standard were separated using liquid-liquid extraction. The extracted sample run through a chromatographic system with an ACE-C18 column (4.6 × 100 mm, 5 μm); the mobile phase consisted of methanol and 2 mM ammonium formate in an 80:20 ratio at a flow rate of 1.00 mL/min. The system operates for three minutes in multiple reaction monitoring mode at the ABSCIEX API 4000 mass spectrometer using electron spray ionization. For capmatinib, the ion transitions are 413.10 to 382.10 and 426.30 to 358.20 for deucravacitinib, with a concentration range of 5.00 to 4000 ng/mL, the accuracy, precision, linearity, selectivity, and selectivity were validated and found to be within the acceptability limits.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
